BlueCross BlueShield Federal Employee Program

GROWTH HORMONE PEDIATRIC PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: 1-877-378-4727

Patient Information (required)			**Provider Information (required)**		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: **R**			Physician Signature:		
PHYSICIAN COMPLETES					

For Standard Option patients Norditropin is a preferred product. Please consider prescribing the preferred product.
Standard Option patients who switch to the preferred product can receive up to 2 fills without a copay for the benefit year.

Growth Hormone Pediatric

NOTE: Form must be completed in its **entirety** for processing

Please select medication:

❑Genotropin	**❑Norditropin**	**❑Saizen**	**❑Zomacton (aka. Tev-Tropin)**
❑Humatrope	**❑Omnitrope**	**❑Sogroya**	

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

Is this request for brand or generic? ❑Brand ❑Generic

1. Is this **INITIATION** of therapy for the patient? ***Please select answer below:***
   ❑ **NO –** this is a PA renewal for **CONTINUATION** of therapy, please answer the questions on **PAGE 3**
   ❑ **YES –** this is **INITIATION** of therapy, please answer the questions below:
2. **Non-Preferred Product Request (Standard Option Patient)**: Would you like to participate in this program and switch the patient to Norditropin? ❑Yes ❑No* ***(*If NO, please answer the following questions)***
   a. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to Norditropin? ❑Yes ❑No*
   ***If NO**, is there a clinical reason for not trying Norditropin? ❑Yes* ❑No
   ***If YES**, please specify: _____
   b. Does the patient require a reduction of treatment burden with fewer injections? ❑Yes ❑No
3. Does the patient have radiographic evidence within the last 12 months of open epiphyses? ❑Yes ❑No
4. Does the patient have evidence of tumor activity or active neoplasm? ❑Yes ❑No
5. Will this medication be used in combination with another somatropin agent such as Serostim, Zorbtive, or any other growth hormone? ❑Yes* ❑No
   ***If YES**, please specify the medication: _____
6. Will this medication be used in combination with Voxzogo (vosoritide)? ❑Yes ❑No
7. **Norditropin Request (Standard Option Patient):** Is this medication being requested as a change from one of the following to allow the member access to their copay benefit: Genotropin, Humatrope, Ngenla, Omnitrope, Saizen, Skytrofa, Sogroya, or Zomacton (formerly Tev-Tropin)? ❑Yes* ❑No
   ***If YES**, select medication: ❑Genotropin ❑Humatrope ❑Ngenla ❑Omnitrope
   ❑Saizen ❑Skytrofa ❑Sogroya ❑Zomacton
8. **Norditropin Request (Basic Option Patient)**: Is this medication being requested as a change from Skytrofa or Sogroya to allow the member access to their copay benefit? ❑Yes* ❑No
   ***If YES**, select medication: ❑Skytrofa ❑Sogroya

PLEASE PROCEED TO PAGE 2 FOR DIAGNOSES

BlueCross BlueShield Federal Employee Program

GROWTH HORMONE PEDIATRIC PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: 1-877-378-4727

PAGE 2 - PHYSICIAN COMPLETES

Patient Name: _____ DOB: _____ Patient ID: R _____

9. What is the patient's diagnosis?

❑Noonan syndrome ❑Prader-Willi syndrome ❑Turner syndrome
❑SHOX (short stature homeobox-containing gene deficiency)

❑Child was born small for gestational age
a. Has the patient failed to manifest catch-up growth by age 2 to 4? ❑Yes ❑No

❑Chronic renal insufficiency
a. Has the patient had a renal (kidney) transplant? ❑Yes ❑No

❑Growth hormone deficiency (inadequate secretion of endogenous growth hormone)
a. Is the growth hormone stim test level less than 10? ❑Yes ❑No* ❑This test has not been done*
***If NO OR Test Has Not Been Done**, please answer the following questions:
i. Is the IGF-1 level subnormal for the patient's age? ❑Yes ❑No ❑This test has not been done
ii. Is the IGFBP-3 level subnormal for the patient's age? ❑Yes ❑No ❑This test has not been done
b. Is the patient's height below the 3rd percentile for age? ❑Yes ❑No*
***If NO**, is the growth hormone deficiency due to CNS lesions? ❑Yes ❑No

❑Idiopathic Short Stature (ISS) aka non-growth hormone-deficient short stature
a. Is the patient's height standard deviation score (SDS) less than or equal to -2.25? ❑Yes ❑No
b. Has it been determined that the growth rate will not permit attainment of adult height in normal range? ❑Yes ❑No
c. Did the diagnostic evaluation exclude other causes associated with short stature that should be observed or treated by other means? ❑Yes ❑No

❑Other ***(please specify)***: _____

BlueCross BlueShield Federal Employee Program

GROWTH HORMONE PEDIATRIC PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: 1-877-378-4727

Patient Information (required)			**Provider Information (required)**		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: **R**			Physician Signature:		
PHYSICIAN COMPLETES					

For Standard Option patients Norditropin is a preferred product. Please consider prescribing the preferred product.
Standard Option patients who switch to the preferred product can receive up to 2 fills without a copay for the benefit year.

CONTINUATION OF THERAPY (PA RENEWAL)
Growth Hormone Pediatric

NOTE: Form must be completed in its **entirety** for processing

Please select medication:

❑Genotropin	**❑Norditropin**	**❑Saizen**	**❑Zomacton (aka. Tev-Tropin)**
❑Humatrope	**❑Omnitrope**	**❑Sogroya**	

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

Is this request for brand or generic? ❑Brand ❑Generic

1. Is this **INITIATION** of therapy for the patient? ***Please select answer below:***
   - ❑ **YES** – this is **INITIATION** of therapy, please answer the questions on **PAGE 1**
   - ❑ **NO –** this is a PA renewal for **CONTINUATION** of therapy, please answer the questions below:
2. **Non-Preferred Product Request (Standard Option Patient)**: Would you like to participate in this program and switch the patient to Norditropin? ❑Yes ❑No***** ***(*If NO, please answer the following questions)***
   a. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to Norditropin? ❑Yes ❑No*
   ****If NO***, is there a clinical reason for not trying Norditropin?
   b. Does the patient require a reduction of treatment burden with fewer injections? ❑Yes ❑No
3. What is the patient's diagnosis?
   - ❑Noonan syndrome
   - ❑Prader-Willi syndrome
   - ❑Turner syndrome
   - ❑Chronic renal insufficiency
     a. Has the patient had a renal (kidney) transplant? ❑Yes ❑No
   - ❑Child was born small for gestational age
     a. Has the patient failed to manifest catch-up growth by age 2 to 4? ❑Yes ❑No
   - ❑Growth hormone deficiency (inadequate secretion of endogenous growth hormone)
   - ❑Idiopathic Short Stature (ISS) aka non-growth hormone-deficient short stature
   - ❑SHOX (short stature homeobox-containing gene deficiency)
   - ❑Other ***(please specify)*:** _____
4. Does the patient have radiographic evidence within the last 12 months of open epiphyses? ❑Yes ❑No
5. Does the patient have evidence of tumor activity or active neoplasm? ❑Yes ❑No
6. Does the patient have a growth velocity of more than 2cm per year? ❑Yes ❑No
7. Is the patient experiencing any significant side effects? ❑Yes ❑No
8. Has the patient been compliant with therapy? ❑Yes ❑No
9. Will this medication be used in combination with another somatropin agent such as Serostim, Zorbtive, or any other growth hormone? ❑Yes***** ❑No ****If YES***, please specify the medication: _____
10. Will this medication being used in combination with Voxzogo (vosoritide)? ❑Yes ❑No